Study of Clinical Performance and Safety of Treatments in Degenerative Meniscopathy With Injection of Polynucleotides

Exclusion Criteria

• •1. Radiographic osteoarthritis of the knee in any compartment greater than Kellgren-Lawrence (KL) grade 3.
• •2. Presence of bone marrow edema (BME) at the index knee.
• •3. Presence of knee instability.
• •4. Have a varus or valgus knee deformity \> 5 degrees.
• •5. Have meniscal roots tears.
• •6. Have discoid meniscus.
• •7. Have patella instability or non-anatomically positioned patella.
• •8. Have a knee flexion contracture \> 10 degrees.
• •9. Be unable to flex the knee to 90 degrees.
• •10. Have a leg length discrepancy causing a noticeable limp.
• •11. Have an active infection or tumor.
• •12. Have any type of knee joint inflammatory disease including Sjogren's syndrome.
• •13. Have neuropathic knee osteoarthropathy, also known as Charcot joint.
• •14. Any disorder or impairment that would interfere with evaluation of outcomes measures, such as neurological, degenerative muscular, psychiatric or cognitive conditions.
• •15. Participation to another clinical trial or clinical investigation in the previous 3 months.
• •16. BMI \> 35.
• •17. Prior knee arthroscopy within 6 months of study enrolment.
• •18. Unable to have an MRI scan.
• •19. Known allergy, sensitivity or intolerance to any of the components of the investigational device or to products originating from fish.
• •20. Positive history of human immunodeficiency virus antibodies, hepatitis B surface antigen or hepatitis C virus antibodies.
• •21. Autoimmune diseases, rheumatoid disease eg. Lupus erythematosus.
• •22. The subject is currently being treated with radiation and or chemotherapy.
• •23. Previous or ongoing alcohol abuse or dependence, use of illicit drugs within 1 year prior to enrolment.
• •24. Patients who are pregnant or planning to become pregnant during the planned period of participation in the study or who are breastfeeding. Women of child-bearing age must consent to use and actually make use of a highly effective contraceptive method, considered acceptable by the investigator, for the whole study duration.
• •25. Does not agree to participate.